DCM
MACK

DAFNA Capital Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

DAFNA Capital Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-65,438
Closed -$2.6M – 53
2014
Q1 		$2.6M Buy
65,438
+21,912
+50% +$938K 2.23% 13
2013
Q4 		$1.83M Buy
43,526
+20,501
+89% +$594K 1.88% 12
2013
Q3 		$687K Buy
+23,025
New +$806K 0.75% 34

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

DAFNA Capital Management's MACK Position: Q2 2014 in Review

DAFNA Capital Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2014, closing a stake of 65,438 shares — an estimated $2.6M sold.

DAFNA Capital Management first reported a position in MACK in Q3 2013 and held it in 3 quarters. The position peaked at $2.6M in Q1 2014. 121 funds tracked by Wall St. Rank hold MACK as of Q2 2014.

  • DAFNA Capital Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2014 after selling out during the quarter.
  • DAFNA Capital Management sold 65,438 Merrimack Pharmaceuticals, Inc. shares in Q2 2014, an estimated $2.6M.
  • DAFNA Capital Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2013 and held it in 3 quarters.
  • DAFNA Capital Management's Merrimack Pharmaceuticals, Inc. position peaked at $2.6M in Q1 2014.
  • 121 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2014.

Based on DAFNA Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.